Cadonilimab

(Synonyms: AK104)
1 Cited Publications
Avis client

Based on 1 publication(s) in Google Scholar

Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC).

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

  • Pureté: 99.87%
  • CAS No.: 2394841-59-7
  • Masse moléculaire:198.64 kDa
  • Stockage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Activité biologique
  • Chemical Information
  • Pureté et documentation
  • Références
  • Help & FAQs

Publications Citing Use of MedChemExpress (MCE) Cadonilimab

More
MOQ
Minimum order quantity
100 mg

Obtenir un devis En stock

Other size
Obtenir un devis
Please select quantity
Amount: USD 0.00